	US 12,403,152 B2
	Compositions and methods using a nicotinamide adenine dinucleotide (NAD⁺) precursor and at least one ketone or ketone precursor
Bernard Cuenoud, Cully (CH); India C. Severin, Lausanne (CH); and Pascal Steiner, Pully (CH)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Appl. No. 17/254,417
Filed by SOCIETE DES PRODUITS NESTLE S.A., Vevey (CH)
PCT Filed May 24, 2019, PCT No. PCT/EP2019/063428 § 371(c)(1), (2) Date Dec. 21, 2020, PCT Pub. No. WO2019/242983, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/688,045, filed on Jun. 21, 2018.
Prior Publication US 2021/0121488 A1, Apr. 29, 2021
Int. Cl. A23L 33/00 (2016.01); A23L 33/125 (2016.01); A61K 9/00 (2006.01); A61K 31/121 (2006.01); A61K 31/19 (2006.01); A61K 31/455 (2006.01); A61K 31/706 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/706 (2013.01) [A23L 33/125 (2016.08); A23L 33/40 (2016.08); A61K 9/0056 (2013.01); A61K 31/121 (2013.01); A61K 31/19 (2013.01); A61K 31/455 (2013.01); A61P 25/28 (2018.01); A23V 2002/00 (2013.01)]

4 Claims

1. A method of (1) reducing risk, incidence and/or severity of or (2) mitigating deterioration of brain structure and function associated with the onset of Alzheimer's Disease (AD) in an individual in need thereof, the method comprising administering to the individual an effective amount of a composition consisting essentially of Tryptophan and medium chain triglycerides (MCTs).